Definition and characteristics

The incidence of CML is 1.5 per 100,000 cases per year with a median age at diagnosis of 55-60 years. Due to improved treatment options and the availability of targeted tyrosine kinase inhibitors (TKI) against BCR-ABL1, the survival rate and thus the prevalence of the disease has been continuously increasing.

Classification of CML

According to the WHO classification 2017, CML is a myeloproliferative neoplasm and is characterized by the presence of a BCR-ABL1 rearrangement. Based on clinical and hematological criteria, three phases can be distinguished in CML: the chronic phase (CP-CML), the accelerated phase (AP-CML) and the blast phase ("blast crisis"; BP-CML).

CML WHO Classification 2017
(Swerdlow et al. 2017)

Myeloproliferative neoplasm

Chronic myeloid leukemia (CML), BCR-ABL1-positive

 

Table 1 compares the criteria for defining the accelerated phase and blast crisis according to WHO 2017 and ELN (European LeukemiaNet) 2013 & 2020.

Table 1: Comparison of criteria for the definition of the accelerated phase and blast crisis according to WHO 2017 (Swerdlow et al. 2017) and ELN 2013 (Baccarani et al. 2013), the latter are also valid in the updated ELN recommendation (Hochhaus et al. 2020)  

 Accelerated phase

Blast phase

WHO 2017

ELN 2013

WHO 2017

ELN 2013

Spleen

Persistent or increasing splenomegaly, unresponsive to therapy---

Leukocytes

Persistent or increasing high white blood cell count (>10 x109/l), unresponsive to therapy---

Blast in PM or BM

10-19%15-29% or
blasts + promyelocytes ≥30% with blasts <30%

≥20%

≥30%

Basophils im PB

≥20%≥20%--

Thrombozytosis / Thrombocytopenia
 

>1000 x109/l, unresponsive to therapy
<100 x 109/l, unrelated to therapy
<100 x 109/l, unrelated to therapy--
Clonal chromosomal abnormalities in Ph+ cells at diagnosis++--
Extramedullary blast proliferation, apart from spleen--++

Diagnostics of CML

Cytomorphology

The cytomorphology serves to secure the diagnosis and is essential to delineate from other myeloproliferative diseases. Furthermore, it is relevant for the classification of CML into chronic phase, accelerated phase and blast crisis. In follow-up examinations under therapy, hematological remission is assessed according to cytomorphological criteria.

Immunophenotyping

Immunophenotyping is not part of the standard diagnostic program in CML at the time of initial diagnosis or in remission. However, it is important in the case of a blast phase (BP) to distinguish myeloid BP from BP of lymphatic origin.

Chromosome analysis

The translocation t(9;22)(q34;q11) is characteristic for CML

According to the WHO classification, the detection of a Philadelphia chromosome (Ph+) or a BCR-ABL1 rearrangement is a requirement for diagnosing CML. Cytogenetically, the so-called Philadelphia chromosome is present, which usually results from a reciprocal translocation between the long arm of chromosome 9 and the long arm of chromosome 22 (t(9;22)(q34;q11)). This leads to a fusion on the molecular level between the ABL1 (Abelson) gene located on the long arm of chromosome 9 and the BCR (breakpoint cluster region) gene located on the long arm of chromosome 22. This so-called standard Philadelphia translocation is found in about 90% of CML patients. The remaining patients with CML show either variant translocations (Marzocchi et al. 2011), in which one or more additional chromosomes are involved in the translocation in addition to chromosomes 9 and 22, or an unremarkable karyotype (Hagemeijer et al. 1993). In the case of an inconspicuous karyotype, a BCR-ABL1 fusion gene is also found at the molecular level, which can be detected by fluorescence in situ hybridisation (FISH) and/or polymerase chain reaction (PCR). In these patients, the BCR-ABL1 fusion gene develops as a result of sub-microscopic insertions of parts of the ABL1 gene into the BCR locus, more rarely of BCR parts into the ABL1 locus (cytogenetically cryptic BCR-ABL1 rearrangement). This subgroup is called Philadelphia-negative, BCR-ABL1-positive CML (Hagemeijer et al. 1993). With regard to clinical picture, disease progression, response to therapy and survival, both groups of patients do not differ from patients with classic, Philadelphia-positive CML according to the data available to date.

For a valid result at least 20 metaphases should be evaluated (ISCN, ELN). Chromosomal analysis also allows an assessment of cytogenetic remission.

The presence of additional abnormalities in addition to translocation 9;22 at initial diagnosis or during the course of the disease can influence the prognosis (see Prognosis) and is of therapeutic relevance (see Therapy).

The occurrence of clonal chromosomal abnormalities in Philadelphia-negative clones under TKI-therapy must be distinguished from this. The detection of such changes is of prognostic importance (see Prognosis).

FISH

FISH: rapid diagnostic validation of interphase nuclei and metaphases

The FISH analysis can confirm or exclude the presence of a BCR-ABL1 rearrangement within 24 hours. Using FISH on interphase nuclei, 100 to 200 cells can be checked for the presence of a BCR-ABL1 rearrangement. This technique can also be used to confirm the diagnosis in patients with Philadelphia-negative, BCR-ABL1-positive CML (i.e. cytogenetically cryptic BCR-ABL1 rearrangement) - in this case a FISH analysis according to the recommendation of the ELN is obligatory (Hochhaus et al. 2020). Furthermore, FISH can be used to check the cytogenetic response to therapy on interphase nuclei as well as on metaphases. However, molecular genetic methods are much more sensitive for the determination of residual disease and are therefore obligatory for monitoring under therapy according to the ELN recommendation (Hochhaus et al. 2020).

Molecular genetics

Control of therapy response and mutation analysis in case of therapy resistance

Molecular genetics with the methods of PCR and sequencing play the central role in CML diagnostics. In addition to diagnosis (detection of the BCR-ABL1 rearrangement), these diagnostic methods are now routinely used both to monitor the response to therapy (BCR-ABL1 expression level) (see Table 2) and to identify resistance mutations in the event of therapy failure.

Molecular response must be calculated according to the International Scale

The BCR-ABL1 expression level is quantified by real-time PCR. The method of RQ-PCR (quantitative real-time PCR) has the necessary high sensitivity of up to 10-5 (1 in 100 000). The molecular response (MR) is determined according to defined criteria (see Table 2). A good molecular response (MMR) is achieved when ≤0,1000% BCR-ABLIS (% BCR-ABL1/ABL1 according to International Scale) is measured.

The value of % BCR-ABL1/ABL1 according to International Scale (IS) is calculated by multiplying the value of % BCR-ABL1/ABL1 determined in the individual laboratory by the laboratory specific conversion factor. The laboratory-specific conversion factor is determined anew each year in comparison with a reference laboratory and enables a comparison of the % BCR-ABL1/ABL1 values between different laboratories. The response is defined by % BCR-ABL1/ABL1 to IS and the log reduction related to the IRIS baseline (corresponds to 100%). Furthermore, for the assignment of an MR status, the corresponding sensitivity must be achieved, which is represented by the sum of the ABL1 copies in the performed measurements.

Table 2: Molecular response criteria (according to Cross et al. 2015), supplemented according to Hochhaus et al. 2020

Response

% BCR-ABL1/ABL1 transcript level on the IS (International scale)

Log reduktion based on the IRIS baseline

Minimum sum of reference gene transcripts

MR4

≤ 0,0100

410 000 *

MR4.5

≤ 0,0032

4,532 000

MR5

≤ 0,001

5100 000

*Each value of the double measurement must be at least 10,000, otherwise no MR status may be assigned.

BCR-ABL1 mutations

In patients treated with TKI, there is in some cases an association between the rebound of BCR-ABL1 expression and the emergence of TKI resistance. In this situation, sequencing for BCR-ABL1 mutations should therefore be performed. Since certain mutations mediate resistance to individual tyrosine kinase inhibitors and other TKI may still be effective, the exact definition of the mutation is important for further therapeutic decisions (e.g. Hochhaus et al. 2020). In contrast to classical Sanger sequencing, next-generation sequencing (NGS) can also detect mutations with an allele content of 3-15%, which Soverini et al. refer to as "minor mutations" or "low-level mutations" (Soverini et al. 2013, Soverini et al. 2020). Since such subclones can expand in the course of therapy and mediate resistance to therapy, the early and sensitive detection of these mutations plays an increasingly important role in therapy decisions (Baer et al. 2016, Soverini et al. 2017 & 2020). A first prospective study underlines the clinical benefit of NGS for the sensitive detection of BCR-ABL1 mutations in CML patients with suboptimal therapy response (Soverini et al. 2020).

BCR-ABL1 independent gene mutations

For a long time, CML was regarded as genetically uniform, but current molecular genetic research in this field paints a more heterogeneous picture. In CP-CML, mutations in seven genes were described as recurrent in more than one study: ASXL1, DNMT3A, TET2, KMT2D, JAK2, RUNX1 and TP53 (Branford et al. 2019). The complexity of the mutation landscape increases significantly as the disease progresses into an acute or blast phase (Branford et al. 2019, Awad et al. 2020). In this advanced stage of the disease, the most common BCR-ABL1 independent mutations are: RUNX1 mutations (18.3%), ICFZ1 exon deletions (16.0%), and ASXL1 mutations (15.1%) (Branford et al. 2019). ICFZ1 abnormalities are strongly associated with a lymphoblastic blast crisis, while ASXL1 mutations are mainly associated with a myeloid blast crisis (Mullighan et al. 2008, Grossmann et al. 2011, Branford et al. 2018).

In many studies on the mutation landscape in CP-CML diagnosis ASXL1 is the most frequently mutated gene (Ernst et al. 2016, Baer et al. 2017, Kim et al. 2017, Branford et al. 2018 and 2019, Nteliopoulos et al. 2019, Awad et al. 2020). In a meta-analysis of 15 different studies the incidence was 9.7% (Branford et al. 2019). The fact that ASXL1 mutations are also found in children and young adults with CP-CML (Ernst et al. 2018) suggests that ASXL1 mutations in the context of CML cannot be explained exclusively as an age-related phenomenon (see CHIP in hematology).

Some small retrospective studies indicate that the occurrence of mutations, especially in the ASXL1 gene, correlates with therapy failure (Schnittger et al. 2014, Baer et al. 2017, Branford et al. 2018, Nteliopoulos et al. 2019, Awad et al. 2020), whereas this correlation was not found in another study (Elena et al. 2016). There is also initial evidence for a possible link between BCR-ABL1 independent changes and disease progression (Branford et al. 2018, Nteliopoulos et al. 2019, Awad et al. 2020).

Prognosis of CML

Clinical prognosis scores

In each era of CML therapy, risk assessment scores based purely on clinical parameters have been developed; Table 3 provides an overview.

Table 3: Comparison of different clinical scores for risk stratification in CML 

  
 

Score

Sokal (1984)Hasford (1998)EUTOS (2011)ELTS (2016)
 Treatment era

Busulfan/Splenectomy +
intensive chemotherapy

 

Interferon alphaImatinibImatinib
Prediction forSurvivalSurvivalAchievement of complete cytogenetic remission within 18 monthsCML caused mortality
Risk groups3323
Clinical parameterAgexx-x
Spleen sizexxxx
Platelet count (/nl)xx-x
Blasts in peripheral blood (%)xx-x
Blood basophils (%)-xx-
Blood eosinophils (%)-x--

The EUTOS long term survival (ELTS) score described in 2016 has the greatest prognostic relevance in the current era of tyrosine kinase inhibitors (Geelen et al. 2018) and should therefore be used for risk stratification according to the ELN's recommendation (Hochhaus et al. 2020). The ELTS score differs from the Socal score, which uses the same parameters for risk classification, in the weighting of the parameters (Hochhaus et al. 2020).

The ELTS score is based on a study by Pfirrmann et al. that examined CML-related mortality under first-line imatinib therapy. Age, spleen size, blasts in the blood and platelet count were identified as prognostic factors for CML-related mortality. The stratification based on the specially developed ELTS score allowed the classification of the 2205 evaluable study participants into three risk groups, the majority of patients (61%) were in the low risk group, 12% were assigned to the high risk group. The probability of CML-related deaths over an 8-year period was 11% (high risk), 6% (intermediate risk), and 2% (low risk). Stratification according to the ELTS score also had prognostic relevance with regard to overall survival; the 8-year survival probability was 81% for patients in the high risk group, 84% for patients with intermediate risk and 93% in the low risk group (Pfirrmann et al. 2016).

Calculation of prognosis

Here you get to the prognosis calculation of the ELTS score.

Additional cytogenetic abnormalities are sometimes associated with a less favourable prognosis

In up to 10% of patients, additional cytogenetic abnormalities are observed in addition to the Philadelphia translocation at the time of initial diagnosis. The proportion of patients with additional abnormalities increases in the course of the disease and amounts to approx. 30% in the accelerated phase (Cortes et al. 2003) and 60-80% in the blast crisis (Anastasi et al. 1995, Johansson et al. 2002, Chen et al. 2017, Hehlmann et al. 2020).

Such additional chromosomal changes are a sign of disease progression. In addition to point mutations in the ABL1 kinase domain, they also represent a possible cause of TKI resistance. Additional abnormalities can be observed even before the clinical symptoms of a blast crisis appear (Marin et al. 2008). The time interval between the occurrence of additional abnormalities and the beginning of the blast phase depends on the type of additional aberration (Gong et al. 2017). For the high-risk abnormalities described by Gong et al. (isochromosome 17q (i(17q)), aberrations of chromosome 7 (-7/del(7q)), 3q26 rearrangements, complex karyotype (≥ 2 aberrations besides t(9;22)) a rapid progress was described, so that in these patients a blast crisis occurred in the median ~2 months after the occurrence of the additional abnormalities (Gong et al. 2017).

A classification of the additional abnormalities can be made according to their frequency. A distinction is made between additional abnormalities of the so-called "major route" (trisomies of chromosomes 8 and 19, i(17q), additional Philadelphia chromosome) and the "minor route" (e.g. -7, -17, +17, +21, -Y and t(3;21)). The occurrence of "major route" additional abnormalities was associated with a worse prognosis and a higher rate of progression to the acceleration phase or blast crisis (Fabarius et al. 2011).

However, more recent data allow a classification of the individual cytogenetic additional abnormalities on the basis of their prognostic significance (Wang et al. 2016, Gong et al. 2017, Hehlmann et al. 2020). On this basis the ELN recommends a distinction between "high-risk" and "low-risk" additional abnormalities. The "high-risk" additional abnormalities are counted as "high-risk": Trisomy 8 and 19, additional Philadelphia chromosome, i(17q), -7/del(7q), aberrations of 11q23 and 3q26.2 and a complex karyotype. All other additional abnormalities belong to the "low-risk" group (Hochhaus et al. 2020). "High-risk" additional abnormalities predict a worsened response to therapy as well as an increased risk of progression (Hochhaus et al. 2020), they are therefore taken into account in therapy planning (see Therapy).

Indication of worsening of prognosis in the presence of Philadelphia negative clones

Philadelphia-negative clones can be detected in cytogenetic remission in 5-10% of patients during therapy for CML with tyrosine kinase inhibitors (Abruzzese et al. 2007, Deininger et al. 2007, Jabbour et al. 2007, Baccarani et al. 2013). The most frequent cytogenetic changes in chronic myeloid leukemia are the loss of the Y chromosome (-Y) and trisomy 8 (+8). The significance of such Philadelphia-negative clones has long been considered largely unclear (Abruzzese et al. 2007, Deininger et al. 2007, Jabbour et al. 2007, Marin et al. 2008, Groves et al. 2011). However, more recent data indicate a less favourable prognosis for these patients if the Philadelphia negative clone does not only show a loss of the Y chromosome (Issa et al. 2017).

In individual cases, an association with the development of MDS or AML has been described for the occurrence of Philadelphia negative clones - especially in the presence of monosomy 7 or the existence of cytopenia or dysplasia (Groves et al. 2011, Issa et al. 2017). The occurrence of chromosome 7 abnormalities or dysplasias was also associated with a deteriorated deep molecular response to TKI (Bidet et al. 2019).

Quality of response after 3 months predictive of deep molecular remission

The depth of the molecular response after three months is a prognostic factor for whether CML patients achieve deep molecular remission (MR4.5) after 18 months. According to ELN criteria, patients should optimally have achieved a good molecular response with BCR-ABL1/ABL1 after IS of ≤10% after 3 months. If this is not the case, TKI resistance may be caused by one or more BCR-ABL1 mutations and may require a change of TKI depending on the mutation status (Hochhaus et al. 2020). Achieving deep molecular remissions minimizes the risk of losing complete cytogenetic remission or MMR. However, it has not yet been conclusively clarified whether deeper molecular remission is associated with longer survival in chronic myeloid leukemia (Falchi et al. 2013, Hehlmann et al. 2014, Kantarjian & Cortes 2014).

Therapy of CML

In addition to the disease phase, therapy planning for CML also takes into account potential comorbidities as well as the possibility of a TKI discontinuation. A continuous diagnostic monitoring allows the assessment of therapy response - and therapeutic intervention in case of insufficient response, resistance, intolerance or progression. In the following, various aspects of the CML therapy algorithm are described in further detail; an overview of therapeutic decision making is also depicted in Figure 1. (Note: Click on the figure to enlarge it.)

Figure 1: Decision making in CML therapy, according to Onkopedia Leitlinie CML 2018, Cortes 2020 and Hochhaus et al. 2020.

Molecular response is crucial for the course of therapy in CML

The molecular genetic analysis of the BCR-ABL1 transcripts plays a key role in therapy monitoring. At initial diagnosis, the determination of the present transcript type is obligatory (Hochhaus et al. 2020). This is a prerequisite for molecular monitoring in the course of therapy using RQ-PCR, which is now the standard in CML diagnostics (see Table 4 and Diagnostics of CML, molecular genetics). The molecular response to TKI therapy is a decisive prognostic parameter with consequences for further therapy planning (see Table 5 and Figure 1).

Table 4: Diagnosis of CML according to European LeukemiaNet (ELN) (with modifications to Hochhaus et al. 2020)

MethodTime of investigation

At diagnosis

during the course

Therapy failure / resistance

(suspected) progression

Zytomorphology

x

x

every 2 weeks until complete hematological remission, more often in case of hematological toxicity 

-

x

Determination of blast percentage 

Immunophenotyping

-

-

-

Differentiation between myeloid and lymphatic blasts

Chromosome analysis

(bone marrow)

x

-

x

Proof /

Exclusion of additional aberrations

x

Proof /

Exclusion of additional aberrations

FISH

(x) in Ph-negative cases(x) for atypical BCR-ABL1 transcript

-

-

Molecular genetics

x

Qualitative PCR to detect the BCR-ABL1 fusion and determine the transcript type; optional: RQ-PCR

x

RQ-PCR every 3 months, even after reaching MMR

x

Mutation analysis of the ABL1 kinase domain

x

Mutation analysis of the ABL1 kinase domain

Definition of the molecular response to tyrosine kinase inhibitors (TKI)

The definition of optimal response to treatment for CML with a TKI or therapy failure is shown in Table 5 and Figure 1. Between optimal response and treatment failure lies a warning range in which patients require close monitoring. In the event of therapy failure, the ELN recommends that a change in therapy to an alternative TKI should be considered. A change of therapy should always be preceded by a BCR-ABL1 mutation analysis in order to be able to make the optimal choice for an alternative TKI, depending on the type of point mutation in the ABL1 kinase domain (Baccarani et al. 2013, Hochhaus et al. 2020). Mutation analysis is also recommended in case of repeated doubling of the BCR-ABL1/ABL1 value (in %), suboptimal response or primary resistance.

Risk-based classification of additional chromosomal abnormalities important for therapy planning

The occurrence of "high-risk" additional chromosomal abnormalities after ELN (cf. prognosis) is considered a warning signal at the initial diagnosis and in the course of the treatment as a failure (cf. Table 5 and Figure 1). The ELN recommends treating these patients as high-risk patients, which requires close monitoring and possibly a change or intensification of therapy (Hochhaus et al. 2020) (see Table 5 and Figure 1). For "low-risk" patients, the ELN recommendations require the same procedure as for patients without additional chromosomal abnormalities.

Table 5: Definition of the response to TKI (according to Hochhaus et al. 2020)

TimeFailureWarning (close monitoring necessary)Optimal

Baseline

 

 
  • High-risk ELTS-Score
  • "high-risk" ACA*
 
 

3 months

 
  • >10% BCR-ABL1/ABL1

if confirmed within 1-3 months

 
  • >10% BCR-ABL1/ABL1
 
 
  • ≤10% BCR-ABL1/ABL1
 

6 months

 
  • >10% BCR-ABL1/ABL1
 
 
  • >1-10% BCR-ABL1/ABL1
 
 
  • ≤1% BCR-ABL1/ABL1

 

12 months

 
  • >1% BCR-ABL1/ABL1
 
 
  • >0.1-1% BCR-ABL1/ABL1
 
 
  • ≤0.1% BCR-ABL1/ABL1
 
Any time 
  • >1% BCR-ABL1/ABL1
  • resistance mutations
  • „high-risk“ ACA*
 
 
  • >0,1-1% BCR-ABL1/ABL1
  • Loss of  ≤0.1% BCR-ABL1/ABL1 (MMR)
 
 
  • ≤0.1% BCR-ABL1/ABL1
 

*"high-risk" additional chromosomal abnormalities after ELN: +8, + 19, additional Philadelphia chromosome, i(17q), -7/del(7q), 11q23 aberrations, 3q26.2 aberrations, complex karyotype

Therapy-free remission

Several studies have shown that discontinuation of TKI treatment (TKI stop) is possible and safe after achieving and maintaining deep molecular remission (Campiotti et al. 2017, Narra et al. 2017, Saussele et al. 2018). Depending on the study, 40-55% of patients remained in molecular remission, although the factors predicting recurrence are still the subject of current research (Hochhaus et al. 2019). In the updated ELN recommendations, criteria for a TKI stop are given (Table 6 and Figure 1).

Table 6: Requirements  for tyrosine kinase inhibitor discontinuation  (according to Hochhaus et al. 2020)

Mandatory

Minimal (TKI stop allowed)

Optimal (stop recommended for consideration)
Patient in first chronic phase

First-line therapy or second-line if intolerance was the only reason for changing TKI

Duration of TKI therapy >5 years

Motivated patient with structured communication

Typical e13a2 or e14a2 BCR–ABL1 transcripts

Duration of DMR > 3 years if MR4

Access to high quality quantitative PCR using the International Scale (IS) with rapid turn-around of PCR test resultsDuration of TKI therapy >5 years (>4 years for 2GTKI)Duration of DMR > 2 years if MR4.5
Patient’s agreement to more frequent monitoring after stopping treatment. This means monthly for the first 6 months, every 2 months for months 6–12, and every 3 months thereafterDuration of DMR (MR4 or better) >2 years

 

 

No prior treatment failure

 

Recurrences after TKI stop is basically possible and usually occurs within the first 6-8 months after TKI stop (Saußele et al. 2016, Hochhaus et al. 2020). The loss of the major molecular response (MMR) is considered a recurrence (Rousselot et al. 2014). In this case, treatment should be resumed. By reinitiating therapy with the same TKI, a molecular response could be achieved again in the vast majority (90-95%) of patients (Hochhaus et al. 2020).

Overview of clinical studies of the German CML Alliance

The linked PDF document from the University Hospital of Jena provides an overview of currently recruiting clinical studies for adult CML patients of the German CML Alliance. Currently, the information is only available in German.

References

Abruzzese E et al. Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer 2007;109(12):2466-2472.

Anastasi J et al. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia 1995;9(4):628-633.

Awad SA et al. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances 2020;4(3):546–559.

Baccarani M et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122(6):872-884.

Baer CR et al. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica 2016;101: 830-838.

Baer CR et al. Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment. Blood 2017;130 (Suppl 1):1585.

Bidet A et al. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica 2019;104(6):1150-1155.

Branford S et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood 2018;132(9):948-961.

Branford S et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 2019;33(8):1835-1850.

Campiotti L et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer 2017;77:48–56.

Chen Z et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 2017;31(3):585-592.

Cortes J. How to manage CML patients with comorbidities. Blood 2020;136(22):2507-2512.

Cortes JE et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101(10):3794-3800.

Cross NC et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015;29(5):999-1003.

Deininger MW et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 2007;110(7):1509-1519.

Elena C et al. Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors. Blood 2016;128(22):1117.

Ernst T et al. Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia 2018;32(9):2046-2049.

Ernst T et al. Prevalence and Dynamics of BCR-ABL Independent Gene Mutations in Patients with Chronic Myeloid Leukemia. Blood 2016;128(22):1221.

Fabarius A et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011;118(26):6760-6768.

Falchi L et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013;88(12):1024-1029.

Geelen IGP et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients. Leukemia 2018;32(10):2299-2303.

Gong Z et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017;1(26):2541-2552.

Grossmann V et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011;25(3):557-560.

Groves et al. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer Genetics 2011;204(1):39-44.

Hagemeijer et al. Genes Chromosomes Cancer: Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia. Genes Chromosomes Cancer 1993;8(4):237-245.

Hasford J et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90(11):850-858.

Hasford J et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 2011;118(3):686-692.

Hehlmann R et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014;32(5):415-423.

Hehlmann R et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020;doi: 10.1038/s41375-020-0826-9.

Hochhaus A et al. Absetzen der CML-Therapie –„therapiefreie Remission“. Journal Onkologie 2019;7/8:49-52.

Hochhaus A et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966–984.

Issa GC et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment. Blood 2017;130(19):2084-2091.

Jabbour E et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110(8):2991-2995.

Johansson B et al. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107(2):76-94.

Kantarjian H, Cortes JE. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol 2014;32(27):3077.

Kim T et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood 2017;129(1):38-47.

Marin D et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112(12):4437-4444.

Marzocchi G et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood 2011;117(25):6793-6800.

Mullighan CG et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453(7191):110-114.

Narra RK et al. Chronic Myeloid Leukemia- The Promise of Tyrosine Kinase Inhibitor Discontinuation. Curr Hematol Malig Rep. 2017;12(5):415–423.

Nteliopoulos G et al. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors. Haematologica 2019; pii: haematol.2018.200220.

Onkopedia Leitlinie „Chronische Myeloische Leukämie (CML)“; DGHO 2018.

Pfirrmann M et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016;30(1):48-56.

Rousselot P et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–30.

Saußele S et al. The Concept of Treatment-Free Remission in Chronic Myeloid Leukemia. Leukemia 2016;30(8):1638-1647.

Saussele S et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, nonrandomised, trial. Lancet Oncol 2018;19:747–757.

Schnittger S et al. CML Patients with Resistance to Tyrosine Kinase Inhibitors and without BCR-ABL1 Resistance Mutation Frequently Carry Other Gene Mutations. Blood 2014;124(21):4516.

Sokal JE et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63(4):789-799.

Soverini S et al.  Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 2013;122(9):1634-1648.

Soverini S et al. What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening. Blood 2017;130(Suppl. 1):248.

Soverini S et al. Prospective Assessment of NGS-detectable Mutations in CML Patients With Nonoptimal Response: The NEXT-in-CML Study. Blood 2020;135(8):534-541.

Swerdlow SH et al. WHO classification of tumours of haematopoetic and lymphoid tissue. International Agency of Research on Cancer 2017; 4. überarbeitete Version.

Wang W et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016;127(22):2742-2750.